Xeris Biopharma Holdings, Inc. XERS Keveyis — Product revenue, net

Other product segments

Similar metrics at other companies

MIRMProduct sales, net — Product sales, net

$159.88M+43.3%

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

GERNProduct revenue, net — Total revenues

$51.77M+31.3%

ESPRProduct sales, net — Total Revenues

$43.4M+24.3%

CRNXProduct revenue, net — Total Revenue

$10.31M—

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net?

Xeris Biopharma Holdings, Inc. (XERS) reported keveyis — product revenue, net of $11.89M in Q1 2026.

How has Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net changed year-over-year?

Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net increased by 4.0% year-over-year, from $11.43M to $11.89M.

What is the long-term trend for Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net?

Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s keveyis — product revenue, net has grown at a 46.4% compound annual growth rate (CAGR), from $10.36M to $47.65M.

What does keveyis — product revenue, net mean?

This metric represents the total net sales generated from the commercialization of a specific therapeutic product after accounting for returns, rebates, and other sales deductions. It serves as a key indicator of the product's market adoption, pricing power, and commercial performance within its specific therapeutic category. Tracking this revenue stream helps investors assess the growth trajectory and lifecycle maturity of the company's specialized pharmaceutical assets.